EQUITY ALERT: The Rosen Law Firm Announces Investigation of Securities Claims Against Sunesis Pharmaceuticals, Inc.

The Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of investors of Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) resulting from allegations that Sunesis Pharmaceuticals may have issued materially misleading business information to the investing public.

On July 23, 2015, Sunesis Pharmaceuticals disclosed that the Food and Drug Administration would not support the filing of a New Drug Application for its proposed leukemia treatment—vosaroxin—because it did not reach statistical significance on the protocol-defined primary analysis of overall survival. On this news, shares of Sunesis Pharmaceuticals fell $2.51 per share or over 70% on July 24, 2015, damaging investors.

The Rosen Law Firm is preparing a class action lawsuit to recover losses suffered by Sunesis Pharmaceuticals investors. If you purchased shares of Sunesis Pharmaceuticals on or before July 23, 2015, please visit the firm’s website at http://rosenlegal.com/cases-679.html for more information. You may also contact Phillip Kim, Esq. or Kevin Chan, Esq. of The Rosen Law Firm toll free at 866-767-3653 or via email at [e-mail] or [e-mail].

The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.

Attorney Advertising. Prior results do not guarantee a similar outcome.

View source version on businesswire.com: http://www.businesswire.com/news/home/20150724005894/en/

The Rosen Law Firm, P.A.Laurence Rosen, Esq.Phillip Kim, Esq.Kevin Chan, Esq.275 Madison Avenue, 34th FloorNew York, NY 10016Tel: [phone]Toll Free: 866-767-3653Fax: [e-mail]@[e-mail]